Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 120Carcinoma, Hepatocellular 69Ovarian Neoplasms 64Neoplasms 36Carcinoma, Non-Small-Cell Lung 35Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 23Colonic Neoplasms 21Breast Neoplasms 19Endometrial Neoplasms 18Neoplasm Metastasis 17Uterine Cervical Neoplasms 15Stomach Neoplasms 15Rectal Neoplasms 15Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Recurrence 7Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5

Interventions

Sirolimus 2temsirolimus 1carbon-11 acetate 1Valproic Acid 1Respiratory Function Tests 1Phlebotomy 1Immunoglobulin G 1Imatinib Mesylate 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Bevacizumab × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡